 |
Myriad Genetics MYGN (news,
chart,
quote) - MYGN volatility Elevated into disappointing Alzheimer's data
MYGN is recently down $5.48 to $42.25 in pre-open trading. MYGN's Flurizan, a treatment for Alzheimer's diseases, had negative Phase 3 results. RBC Capital has a 12-month forward target of $37 on MYGN. MYGN July option implied volatility of 102 was above its 26-week average of 71 according to Track Data, suggesting larger July price movement.
|
|
|
|
